S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in
NYSE:BSX

Boston Scientific Stock Forecast, Price & News

$36.66
+0.39 (+1.08 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$36.07
Now: $36.66
$36.82
50-Day Range
$33.45
MA: $35.24
$36.76
52-Week Range
$24.10
Now: $36.66
$44.44
Volume7.50 million shs
Average Volume11.21 million shs
Market Capitalization$52.49 billion
P/E Ratio14.05
Dividend YieldN/A
Beta0.87
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Boston Scientific logo

MarketRank

Overall MarketRank

2.19 out of 5 stars

Medical Sector

26th out of 1,928 stocks

Surgical & Medical Instruments Industry

3rd out of 170 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP10113710
Phone508-683-4000
Employees36,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.74 billion
Cash Flow$2.42 per share
Book Value$9.96 per share

Profitability

Net Income$4.70 billion

Miscellaneous

Outstanding Shares1,431,921,000
Market Cap$52.49 billion
Next Earnings Date2/3/2021 (Confirmed)
OptionableOptionable
$36.66
+0.39 (+1.08 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Boston Scientific (NYSE:BSX) Frequently Asked Questions

How has Boston Scientific's stock been impacted by COVID-19?

Boston Scientific's stock was trading at $33.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BSX stock has increased by 8.3% and is now trading at $36.66.
View which stocks have been most impacted by COVID-19
.

Is Boston Scientific a buy right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 3 hold ratings, 17 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Boston Scientific stock.
View analyst ratings for Boston Scientific
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Boston Scientific?

Wall Street analysts have given Boston Scientific a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Boston Scientific wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas Greco's approval rating as Boston Scientific's CEO?

538 employees have rated Boston Scientific CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among Boston Scientific's employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Boston Scientific
.

How can I listen to Boston Scientific's earnings call?

Boston Scientific will be holding an earnings conference call on Wednesday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) issued its quarterly earnings data on Monday, November, 2nd. The medical equipment provider reported $0.37 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.25 by $0.12. The medical equipment provider had revenue of $2.66 billion for the quarter, compared to analysts' expectations of $2.52 billion. Boston Scientific had a net margin of 36.59% and a return on equity of 11.77%.
View Boston Scientific's earnings history
.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.71-2.71 billion, compared to the consensus revenue estimate of $2.86 billion.

What price target have analysts set for BSX?

22 equities research analysts have issued 1 year target prices for Boston Scientific's stock. Their forecasts range from $25.00 to $58.00. On average, they expect Boston Scientific's stock price to reach $43.09 in the next year. This suggests a possible upside of 17.5% from the stock's current price.
View analysts' price targets for Boston Scientific
or view Wall Street analyst' top-rated stocks.

Are investors shorting Boston Scientific?

Boston Scientific saw a increase in short interest in December. As of December 31st, there was short interest totaling 16,340,000 shares, an increase of 33.7% from the December 15th total of 12,220,000 shares. Based on an average daily volume of 13,170,000 shares, the days-to-cover ratio is currently 1.2 days.
View Boston Scientific's Short Interest
.

Who are some of Boston Scientific's key competitors?

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), The Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and salesforce.com (CRM).

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the following people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 56, Pay $3.57M)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 55, Pay $1.28M)
  • Mr. Edward F. Mackey, Exec. VP of Global Operations (Age 58, Pay $1.13M)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Interventional Cardiology (Age 57, Pay $1.24M)
  • Mr. Jonathan R. Monson, VP, Global Controller & Chief Accounting Officer
  • Ms. Jodi Euerle Eddy, Sr. VP and Chief Information & Digital Officer (Age 48)
  • Ms. Susan Vissers Lisa, VP of Investor Relations
  • Ms. Desiree Ralls-Morrison, Sr. VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Ms. Catherine Jennings, VP of Global Marketing & New Bus. Devel. of Peripheral Interventions
  • Ms. Wendy Carruthers, Sr. VP of HR (Age 52)

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by many different retail and institutional investors. Top institutional shareholders include DNB Asset Management AS (0.07%), Gateway Investment Advisers LLC (0.06%), Rhenman & Partners Asset Management AB (0.04%), Atalanta Sosnoff Capital LLC (0.04%), Manning & Napier Group LLC (0.03%) and Nexus Investment Management ULC (0.03%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Wendy Carruthers, Williamson Scott and Xin Warren Wang.
View institutional ownership trends for Boston Scientific
.

Which major investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, New England Research & Management Inc., Pacer Advisors Inc., Gateway Investment Advisers LLC, State of Alaska Department of Revenue, Deltec Asset Management LLC, Busey Wealth Management, and Gradient Investments LLC. Company insiders that have sold Boston Scientific company stock in the last year include Daniel J Brennan, David A Pierce, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Maulik Nanavaty, and Wendy Carruthers.
View insider buying and selling activity for Boston Scientific
or view top insider-selling stocks.

Which major investors are buying Boston Scientific stock?

BSX stock was acquired by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Kestra Advisory Services LLC, Rhenman & Partners Asset Management AB, First American Bank, Nexus Investment Management ULC, Manning & Napier Group LLC, Exchange Traded Concepts LLC, and IFM Investors Pty Ltd.
View insider buying and selling activity for Boston Scientific
or or view top insider-buying stocks.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $36.66.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $52.49 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis. Boston Scientific employs 36,000 workers across the globe.

What is Boston Scientific's official website?

The official website for Boston Scientific is www.bostonscientific.com.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.